

APPENDICES

Pandor et al. Risk assessment models for venous thromboembolism in pregnancy and in the puerperium – a systematic review

Contents

Appendix S1	Literature search strategies
Appendix S2	List of excluded studies with rationale
Appendix S3	Simplified summary of widely evaluated generic RAMs, their associated characteristics and composite clinical variables

APPENDIX S1 LITERATURE SEARCH STRATEGIES

Database searched: Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily, Ovid MEDLINE and Versions(R)

Platform or provider used: Ovid SP

Date of coverage: 1946 to February 2021

Search undertaken: February 2021

- 1 Pregnant Women/ or exp Pregnancy Complications/ or exp Maternal Health Services/ or exp Fetal Monitoring/ or exp Prenatal Diagnosis/ or Perinatal Care/ or Labor pain/ or Analgesia, Obstetric/ or exp Obstetric Surgical Procedures/ or exp Postpartum Period/
- 2 (pregnan* or antenatal* or ante-natal* or prenatal* or pre-natal* or gestational* or matern* or perinatal* or peri-natal* or postnatal* or post-natal* or postpartum or post-partum or puerper* or obstetric).mp.
- 3 1 or 2
- 4 pulmonary embolism/ or thromboembolism/ or venous thromboembolism/ or venous thrombosis/ or upper extremity deep vein thrombosis/
- 5 (((venous or vein) adj (thrombosis or thromboses or thrombus or thromboemboli*)) or (dvt or vte) or ((pulmonary or lung) adj3 (embolism or emboli or embolus or emboliz* or thromboemboli*))).ti,ab.
- 6 4 or 5
- 7 editorial/ or news/ or exp historical article/ or anecdotes as topic/ or comment/ or case report/ or (letter or comment).ti.
- 8 randomized controlled trial/ or random*.ti,ab.
- 9 7 not 8
- 10 animals/ not humans/
- 11 exp animals, laboratory/
- 12 exp animal experimentation/
- 13 exp models, animal/
- 14 exp rodentia/
- 15 (rat or rats or mouse or mice).ti.
- 16 9 or 10 or 11 or 12 or 13 or 14 or 15
- 17 6 not 16
- 18 (risk* adj2 assess*).ti,ab.
- 19 ((score* or scoring) adj2 (tool* or system*)).ti,ab.
- 20 ((risk* or predict* or prognos*) adj4 (tool* or rule* or index* or indices or score* or scoring or scale* or model* or system* or algorithm* or stratif* or criteria or calculat*)).ti,ab.
- 21 department of health.ti,ab,au.
- 22 (guidance or guideline*).ti,hw,pt.
- 23 18 or 19 or 20 or 21 or 22
- 24 17 and 23
- 25 3 and 24

Databases searched: EMBASE
Platform or provider used: Ovid SP
Date of coverage: 1974 to February 2021
Search undertaken: February 2021

1 exp pregnancy/ or maternal health service/ or exp pregnancy complication/ or exp fetus monitoring/ or exp prenatal diagnosis/ or exp perinatal care/ or exp obstetric analgesia/ or exp labor pain/ or exp obstetrics/ or obstetric analgesia/ or exp obstetric operation/ or puerperium/
2 (pregnan* or antenatal* or ante-natal* or prenatal* or pre-natal* or gestational* or matern* or perinatal* or peri-natal* or postnatal* or post-natal* or postpartum or post-partum or puerper* or obstetric or labo?r).mp.
3 1 or 2
4 lung embolism/ or exp venous thromboembolism/ or exp vein thrombosis/ or upper extremity deep vein thrombosis/
5 (((venous or vein) adj (thrombosis or thromboses or thrombus or thromboemboli*)) or (dvt or vte) or ((pulmonary or lung) adj3 (embolism or emboli or embolus or emboliz* or thromboemboli*))) .ti,ab.
6 4 or 5
7 editorial/ or comment/ or case report/ or (letter or comment).ti.
8 randomized controlled trial/ or random*.ti,ab.
9 7 not 8
10 exp animal/ not exp human/
11 (rat or rats or mouse or mice).ti.
12 9 or 10
13 6 not 12
14 (risk* adj2 assess*).ti,ab.
15 ((score* or scoring) adj2 (tool* or system*)).ti,ab.
16 ((risk* or predict* or prognos*) adj4 (tool* or rule* or index* or indices or score* or scoring or scale* or model* or system* or algorithm* or stratif* or criteria or calculat*)).ti,ab.
17 department of health.ti,ab,au.
18 (guidance or guideline*).ti,hw,pt.
19 14 or 15 or 16 or 17 or 18
20 13 and 19
21 3 and 20

Databases searched: Cochrane CENTRAL Register of Randomised Controlled Trials & Cochrane Database of Systematic Reviews

Platform or provider used: www.thecochranelibrary.com

Date of coverage: Inception to February 2021

Search undertaken: February 2021

- #1 MeSH descriptor: [Pregnancy] explode all trees
- #2 MeSH descriptor: [Pregnancy Complications] 1 tree(s) exploded
- #3 MeSH descriptor: [Maternal Health Services] explode all trees
- #4 MeSH descriptor: [Fetal Monitoring] explode all trees
- #5 MeSH descriptor: [Perinatal Care] explode all trees
- #6 MeSH descriptor: [Labor Pain] explode all trees
- #7 MeSH descriptor: [Analgesia, Obstetrical] explode all trees
- #8 MeSH descriptor: [Obstetric Surgical Procedures] explode all trees
- #9 MeSH descriptor: [Postpartum Period] explode all trees
- #10 (pregnan* or antenatal* or "ante-natal*" or prenatal* or "pre-natal*" or gestational* or matern* or perinatal* or "peri-natal*" or postnatal* or "post-natal*" or postpartum or "post-partum" or puerper* or obstetric):ti,ab,kw (Word variations have been searched)
- #11 MeSH descriptor: [Pulmonary Embolism] explode all trees
- #12 MeSH descriptor: [Venous Thromboembolism] explode all trees
- #13 MeSH descriptor: [Venous Thrombosis] explode all trees
- #14 MeSH descriptor: [Upper Extremity Deep Vein Thrombosis] explode all trees
- #15 ((venous or vein) near/2 (thrombosis or thromboses or thrombus or thromboemboli*)):ti,ab,kw OR ((dvt or vte):ti,ab,kw OR ((pulmonary or lung) near/2 (embolism or emboli or embolus or emboliz* or thromboemboli*)):ti,ab,kw (Word variations have been searched)
- #16 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10
- #17 #11 or #12 or #13 or #14 or #15
- #18 #16 and #17
- #19 (risk* or predict* or prognos*):ti,ab,kw AND (tool* or rule* or index* or indices or score* or scoring or scale* or model* or system* or algorithm* or stratif* or criteria or calculat*):ti,ab,kw OR ((pulmonary or lung) near/3 (embolism or emboli or embolus or emboliz* or thromboemboli*)):ti,ab,kw (Word variations have been searched)
- #20 (score* or scoring) near/2 (tool* or system*)
- #21 guidance or guideline* or "department of health"
- #22 #19 or #20 or #21
- #23 #18 and #22

APPENDIX S2 LIST OF EXCLUDED STUDIES WITH RATIONALE

	Authors, year	Reason for exclusion
1.	Abdul Sultan et al., 2013 ¹	Not a RAM for predicting the risk of developing VTE in pregnancy or the puerperium
2.	Ahmadzia et al., 2019 ²	Abstract of included full text study (Ellis-Kahana 2020)
3.	Alsayegh et al., 2016 ³	No relevant/useable outcome data
4.	Bahl et al., 2010 ⁴	Not a RAM for predicting the risk of developing VTE in pregnancy or the puerperium
5.	Banfield et al., 2013 ⁵	No relevant/useable outcome data
6.	Bare et al., 2013 ⁶	Not a RAM for predicting the risk of developing VTE in pregnancy or the puerperium
7.	Barros et al., 2017 ⁷	No relevant/useable outcome data
8.	Barros et al., 2017 ⁸	No relevant/useable outcome data
9.	Barros et al., 2020 ⁹	No relevant/useable outcome data
10.	Barros et al., 2011 ¹⁰	No relevant/useable outcome data
11.	Bastek et al., 2011 ¹¹	Not a RAM for predicting the risk of developing VTE in pregnancy or the puerperium
12.	Beckett et al., 2013 ¹²	No relevant/useable outcome data
13.	Berkin et al., 2016 ¹³	No relevant/useable outcome data
14.	Blondon et al., 2015 ¹⁴	Not a RAM for predicting the risk of developing VTE in pregnancy or the puerperium
15.	Blondon and Hugon-Rodin 2017 ¹⁵	Commentary
16.	Campbell 2013 ¹⁶	No relevant/useable outcome data
17.	Cavazza et al., 2010 ¹⁷	Abstract of included full text study (Cavazza 2012)
18.	Chauleur et al., 2017 ¹⁸	Data overlap - patients included in Chauleur 2018 (included study)
19.	Chauleur et al., 2010 ¹⁹	No relevant/useable outcome data
20.	Chauleur et al., 2018 ²⁰	No relevant/useable outcome data
21.	Cooley et al., 2016 ²¹	No relevant/useable outcome data
22.	Creagh et al., 2014 ²²	Not a RAM for predicting the risk of developing VTE in pregnancy or the puerperium
23.	Creagh et al., 2013 ²³	Not a RAM for predicting the risk of developing VTE in pregnancy or the puerperium
24.	Crowley et al., 2013 ²⁴	Abstract of excluded full text study (Crowley 2017)
25.	Crowley et al., 2017 ²⁵	No relevant/useable outcome data
26.	Crowley et al., 2013 ²⁶	Abstract of excluded full text study (Crowley 2017)
27.	Cunningham et al., 2015 ²⁷	Not a RAM for predicting the risk of developing VTE in pregnancy or the puerperium

28.	Cutts et al., 2014 ²⁸	Not a RAM for predicting the risk of developing VTE in pregnancy or the puerperium
29.	Cutts et al., 2011 ²⁹	Not a RAM for predicting the risk of developing VTE in pregnancy or the puerperium
30.	Dargaud et al., 2015 ³⁰	Abstract of included full text study (Dargaud 2017)
31.	Dargaud et al., 2009 ³¹	Data overlap - patients included in Dargaud 2017 (included study)
32.	Dargaud et al., 2009 ³²	No relevant/useable outcome data
33.	Davis and Hadpawat-Lee 2017 ³³	No relevant/useable outcome data
34.	Dentali et al., 2020 ³⁴	Not a RAM for predicting the risk of developing VTE in pregnancy or the puerperium
35.	Francis Kim et al., 2020 ³⁵	No relevant/useable outcome data
36.	Francis Kim et al., 2020 ³⁶	No relevant/useable outcome data
37.	Fuller et al., 2018 ³⁷	Not a RAM for predicting the risk of developing VTE in pregnancy or the puerperium
38.	Gassmann et al., 2020 ³⁸	Abstract of included full text study (Gassmann 2020)
39.	Gerhardt et al., 2016 ³⁹	Not a RAM for predicting the risk of developing VTE in pregnancy or the puerperium
40.	Gherghe et al., 2012 ⁴⁰	No relevant/useable outcome data
41.	Goffman et al., 2009 ⁴¹	No relevant/useable outcome data
42.	Gomez et al., 2020 ⁴²	No relevant/useable outcome data
43.	Grille et al., 2015 ⁴³	No relevant/useable outcome data
44.	Goodfellow et al., 2017 ⁴⁴	No relevant/useable outcome data
45.	Grant et al., 2016 ⁴⁵	No relevant/useable outcome data
46.	Handa et al., 2015 ⁴⁶	No relevant/useable outcome data
47.	Harris et al., 2016 ⁴⁷	No relevant/useable outcome data
48.	Hayes-Ryan and Byrne 2011 ⁴⁸	No relevant/useable outcome data
49.	Hayes-Ryan and Byrne 2012 ⁴⁹	No relevant/useable outcome data
50.	Heath and Goodfellow 2016 ⁵⁰	No relevant/useable outcome data
51.	Henke and Pannucci 2010 ⁵¹	Review
52.	Kazi et al., 2020 ⁵²	Not a RAM for predicting the risk of developing VTE in pregnancy or the puerperium
53.	Lacoss and Jheeta 2017 ⁵³	Not a RAM for predicting the risk of developing VTE in pregnancy or the puerperium
54.	Li et al., 2018 ⁵⁴	Not a RAM for predicting the risk of developing VTE in pregnancy or the puerperium
55.	Lindqvist 2018 ⁵⁵	Letter
56.	Lindqvist and Hellgren 2011 ⁵⁶	No relevant/useable outcome data
57.	Lindqvist et al., 2002 ⁵⁷	No relevant/useable outcome data

58.	Lou Mercade et al., 2017 ⁵⁸	No relevant/useable outcome data
59.	Marks and Maiti 2018 ⁵⁹	No relevant/useable outcome data
60.	Mcarthur et al., 2011 ⁶⁰	No relevant/useable outcome data
61.	Mpouzouki et al., 2013 ⁶¹	No relevant useable outcome data
62.	Naidoo et al., 2019 ⁶²	No relevant/useable outcome data
63.	Nct 2018 ⁶³	Protocol
64.	Noone et al., 2013 ⁶⁴	No relevant/useable outcome data
65.	O'Connor et al., 2011 ⁶⁵	Not a RAM for predicting the risk of developing VTE in pregnancy or the puerperium
66.	O'Keefe et al., 2019 ⁶⁶	Not a RAM for predicting the risk of developing VTE in pregnancy or the puerperium
67.	Omunakwe et al., 2017 ⁶⁷	No relevant/useable outcome data
68.	Orfanelli et al., 2017 ⁶⁸	No relevant/useable outcome data
69.	O'Shaughnessy et al., 2017 ⁶⁹	No relevant/useable outcome data
70.	O'Shaughnessy et al., 2018 ⁷⁰	No relevant/useable outcome data
71.	O'Shaughnessy et al., 2019 ⁷¹	No relevant/useable outcome data
72.	O'Sullivan et al., 2020 ⁷²	No relevant/useable outcome data
73.	O'Sullivan et al., 2009 ⁷³	Not a RAM for predicting the risk of developing VTE in pregnancy or the puerperium
74.	Ottawa Hospital Research Institute and Leo Pharma 2002 ⁷⁴	Protocol
75.	Palmerola et al., 2016 ⁷⁵	No relevant/useable outcome data
76.	Pannucci and Fleming 2017 ⁷⁶	Not a RAM for predicting the risk of developing VTE in pregnancy or the puerperium
77.	Pierce-Williams et al., 2018 ⁷⁷	No relevant/useable outcome data
78.	Potdar et al., 2006 ⁷⁸	No relevant/useable outcome data
79.	Rahim et al., 2020 ⁷⁹	Not a RAM for predicting the risk of developing VTE in pregnancy or the puerperium
80.	Righini et al., 2013 ⁸⁰	Not a RAM for predicting the risk of developing VTE in pregnancy or the puerperium
81.	Righini and Le Gal 2013 ⁸¹	Not a RAM for predicting the risk of developing VTE in pregnancy or the puerperium
82.	Ryan 2019 ⁸²	No relevant/useable outcome data
83.	Saad et al., 2018 ⁸³	Abstract of included full text study (Tran 2019)
84.	Santos et al., 2015 ⁸⁴	No relevant/useable outcome data
85.	Schoenbeck et al., 2011 ⁸⁵	No relevant/useable outcome data
86.	Sellappan et al., 2012 ⁸⁶	Not a RAM for predicting the risk of developing VTE in pregnancy or the puerperium
87.	Shacaluga et al., 2017 ⁸⁷	No relevant/useable outcome data

88.	Tan and Wisdom 2006 ⁸⁸	No relevant/useable outcome data
89.	Tang and Marsden 2011 ⁸⁹	No relevant/useable outcome data
90.	Taylor et al., 2000 ⁹⁰	No relevant/useable outcome data
91.	Testa et al., 2010 ⁹¹	No relevant/useable outcome data
92.	Testa et al., 2013 ⁹²	No relevant/useable outcome data
93.	Touhami et al., 2018 ⁹³	Not a RAM for predicting the risk of developing VTE in pregnancy or the puerperium
94.	Usoro et al., 2019 ⁹⁴	Not a RAM for predicting the risk of developing VTE in pregnancy or the puerperium
95.	Valdre et al., 2016 ⁹⁵	No relevant/useable outcome data
96.	Von Hawrylak 2018 ⁹⁶	No relevant/useable outcome data
97.	Zhang et al., 2020 ⁹⁷	No relevant/useable outcome data

REFERENCES (APPENDIX S2)

1. Abdul Sultan A, West J, Tata LJ, et al. Risk of first venous thromboembolism in pregnant women in hospital: population based cohort study from England. *BMJ (Clinical Research Ed)* 2013;347:f6099. doi: <https://dx.doi.org/10.1136/bmj.f6099>
2. Ahmadzia HK, Ellis-Kahana JK, Sparks AD, et al. 859: Predicting venous thromboembolism in obese pregnant women in a national study. *American Journal of Obstetrics and Gynecology* 2019;220(1 Supplement):S559-S60. doi: <http://dx.doi.org/10.1016/j.ajog.2018.11.882>
3. Alsayegh F, Al-Jassar W, Wani S, et al. Venous Thromboembolism Risk and Adequacy of Prophylaxis in High Risk Pregnancy in the Arabian Gulf. *Current Vascular Pharmacology* 2016;14(4):368-73.
4. Bahl V, Hu HM, Henke PK, et al. A validation study of a retrospective venous thromboembolism risk scoring method. *Annals of Surgery* 2010;251(2):344-50. doi: <https://dx.doi.org/10.1097/SLA.0b013e3181b7fca6>
5. Banfield DA, Page LM, Cotzias CS, et al. Postnatal risk assessment of venous thromboembolism (VTE). *Archives of Disease in Childhood: Fetal and Neonatal Edition* 2013;98(SUPPL. 1) doi: <http://dx.doi.org/10.1136/archdischild-2013-303966.121>
6. Bare LA, De Haan HG, Arellano AR, et al. A simple genetic thrombosis score of five single nucleotide polymorphisms is associated with risk of first venous thrombosis in pregnant women. *Blood* 2013;122(21)
7. Barros V, Hase E, Igai AM, et al. Cancer and venous thromboembolism in pregnancy. *Research and Practice in Thrombosis and Haemostasis* 2017;1(Supplement 1):54. doi: <http://dx.doi.org/10.1002/rth2.12012>
8. Barros V, Igai AM, Bortolotto MR, et al. Obesity and thromboembolic risk during hospitalization in pregnancy: Preliminary results. *Research and Practice in Thrombosis and Haemostasis* 2017;1(Supplement 1):1030.
9. Barros V, Igai A, Fernanda B, et al. Preventing maternal death and morbidity from venous thromboembolism (VTE): Results from a VTE risk score trial during hospitalization. *Research and Practice in Thrombosis and Haemostasis* 2020;4(SUPPL 1):1197-98. doi: <http://dx.doi.org/10.1002/rth2.12393>
10. Barros V, Oliveira A, Spadotto F, et al. Thrombosis risk score in pregnancy: Preliminary results from a model. *Journal of Perinatal Medicine* 2011;39(SUPPL. 1) doi: <http://dx.doi.org/10.1515/jpm-2012-1008>
11. Bastek JA, Dainty E, Srinivas SK, et al. Pulmonary embolism in pregnancy: Do the diagnostic algorithms from non-pregnant populations apply? *American Journal of Obstetrics and Gynecology* 2011;204(1 SUPPL.):S317. doi: <http://dx.doi.org/10.1016/j.ajog.2010.10.834>
12. Beckett V, Graham I, Keriakos R. Audit of prescribing and administration of thromboprophylaxis medication and stockings to in-patients of the obstetric and gynaecological wards at the

- Jessops Wing, Sheffield teaching hospitals. *BJOG: An International Journal of Obstetrics and Gynaecology* 2013;120(SUPPL. 1):437-38. doi: <http://dx.doi.org/10.1111/1471-0528.12301>
13. Berkin JA, Lee C, Landsberger E, et al. Scorecard implementation improves identification of postpartum patients at risk for venous thromboembolism. *Journal of Healthcare Risk Management: The Journal of the American Society for Healthcare Risk Management* 2016;36(1):8-13. doi: <https://dx.doi.org/10.1002/jhrm.21229>
14. Blondon M, Harrington L, Boehlen F, et al. Pre-pregnancy BMI and delivery BMI as risk factors for postpartum VTE: A population-based, case-control study. *Journal of Thrombosis and Haemostasis* 2015;13(SUPPL. 2):106. doi: <http://dx.doi.org/10.1111/jth.12993>
15. Blondon M, Hugon-Rodin J. A clinical risk score to predict the incidence of postpartum venous thromboembolism. *Evidence-Based Medicine* 2017;22(3):98. doi: <http://dx.doi.org/10.1136/ebmed-2017-110680>
16. Campbell MJ. Full audit cycle assessing how current antenatal inpatients are risk assessed for venous thromboembolic (VTE) disease as an inpatient and antenatally at Ninewells Hospital, Dundee, Scotland, October 2012. *BJOG: An International Journal of Obstetrics and Gynaecology* 2013;120(SUPPL. 1):472. doi: <http://dx.doi.org/10.1111/1471-0528.12301>
17. Cavazza S, Rainaldi MP, Bonazzi F, et al. Thromboprophylaxis following cesarean section: A one site prospective pilot study to evaluate the application of a risk score model. *Pathophysiology of Haemostasis and Thrombosis* 2010;37(SUPPL. 1):A4. doi: <http://dx.doi.org/10.1159/000318095>
18. Chauleur C, Gris JC, Laporte S, et al. Implementation of risk score-guided prophylaxis in over 2000 pregnant women at risk of thrombotic events: Impact on morbidity. A quasi-experimental prospective study. *Thrombosis Research* 2017;151(Supplement 1):S107-S08.
19. Chauleur C, Gris JC, Laporte S, et al. Use of the Delphi method to facilitate antithrombotics prescription during pregnancy. *Thrombosis Research* 2010;126(2):88-92. doi: <https://dx.doi.org/10.1016/j.thromres.2010.01.012>
20. Chauleur C, Gris J-C, Laporte S, et al. Benefit of Risk Score-Guided Prophylaxis in Pregnant Women at Risk of Thrombotic Events: A Controlled Before-and-After Implementation Study. *Thrombosis and Haemostasis* 2018;118(9):1564-71. doi: <https://dx.doi.org/10.1055/s-0038-1668524>
21. Cooley SM, Donnelly JC, Deering M, et al. Thrombocalc: Personalized postpartum VTE risk assessment in a high-throughput environment. *American Journal of Obstetrics and Gynecology* 2016;214(1 SUPPL. 1):S26-S27.
22. Creagh MD, Davies B, Webborn A, et al. Practice using a programme for avoidance of venous thrombo-embolism (VTE) in pregnancy; Is post delivery risk assessment undertaken and

- effective? *British Journal of Haematology* 2014;165(SUPPL. 1):44-45. doi: <http://dx.doi.org/10.1111/bjh.12802>
23. Creagh MD, Dehnel A, Rider L, et al. Does systematic risk assessment in pregnancy identify women at risk for venous thromboembolism and so avoid thrombosis? Experience of an 18 month programme based on national guidance. *Journal of Thrombosis and Haemostasis* 2013;11(SUPPL. 2):867.
24. Crowley MP, Noone C, Higgins JR, et al. Venous thromboembolism (VTE) prophylaxis in hospitalized obstetric patients in Ireland: A multicentre cross-sectional study. *Journal of Thrombosis and Haemostasis* 2013;11(SUPPL. 2):739.
25. Crowley MP, Noone C, Higgins JR, et al. A Multicentre Study of Thromboprophylaxis in Pregnancy. *Irish Medical Journal* 2017;110(5):567.
26. Crowley MP, Noone C, Higgins JR, et al. Venous thromboembolism (VTE) prophylaxis in hospitalized obstetric patients: A multicentre cross-sectional study. *Haematologica* 2013;98(SUPPL. 1):438.
27. Cunningham Y, MacDonald H, Coutts S. Bettering antenatal and postnatal risk assessment for venous thromboembolism - A quality improvement approach. *BJOG: An International Journal of Obstetrics and Gynaecology* 2015;122(SUPPL. 2):263. doi: <http://dx.doi.org/10.1111/14710528.13383>
28. Cutts BA, Tran HA, Merriman E, et al. The utility of the Wells clinical prediction model and ventilation-perfusion scanning for pulmonary embolism diagnosis in pregnancy. *Blood Coagulation & Fibrinolysis: An International Journal in Haemostasis and Thrombosis* 2014;25(4):375-8. doi: <https://dx.doi.org/10.1097/MBC.0000000000000054>
29. Cutts BA, Tran H, Merriman E, et al. The utility of the wells clinical prediction model and ventilation-perfusion scanning for pulmonary embolism in pregnancy. *Journal of Thrombosis and Haemostasis* 2011;9(SUPPL. 2):631. doi: http://dx.doi.org/10.1111/j.1538-7836.2011.04380_3.x
30. Dargaud YG, Rugeri L, Fleury C, et al. Individually tailored prophylaxis using a risk score for the management of pregnant women with increased risk of venous thromboembolism. *Blood* 2015;126(23):889.
31. Dargaud Y, Rugeri L, Vergnes MC, et al. A risk score for the management of pregnant women with increased risk of venous thromboembolism: a multicentre prospective study. *British Journal of Haematology* 2009;145(6):825-35. doi: <https://dx.doi.org/10.1111/j.1365-2141.2009.07698.x>
32. Dargaud Y, Rugeri L, Vergnes MC, et al. Management of pregnancies with high risk of thrombosis: A multicenter prospective study. *Journal of Thrombosis and Haemostasis* 2009;7(S2):1060-61. doi: <http://dx.doi.org/10.1111/j.1538-7836.2009.03473-2.x>

33. Davis B, Hadpawat-Lee A. Venous thromboembolism: Comparing risk assessment tools for postpartum prophylaxis in a teaching hospital. *Obstetrics and Gynecology* 2017;129(Supplement 1):114S.
34. Dentali F, Fontanella A, Cohen AT, et al. Derivation and Validation of a Prediction Model for Venous Thromboembolism in Primary Care. *Thrombosis and Haemostasis* 2020;120(4):692-701. doi: <http://dx.doi.org/10.1055/s-0040-1701483>
35. Francis Kim AP, Saleh M, Melendez Torres A, et al. Age and body mass index can screen for VTE risk at labor and delivery admission. *Obstetrics and Gynecology* 2020;135(Supplement 1):39S.
36. Francis Kim AP, Saleh M, Torres AM, et al. Impact of delivery-related factors on venous thromboembolism risk during labor. *Obstetrics and Gynecology* 2020;135(Supplement 1):128S.
37. Fuller GW, Nelson-Piercy C, Hunt BJ, et al. Consensus-derived clinical decision rules to guide advanced imaging decisions for pulmonary embolism in pregnancy and the postpartum period. *European Journal of Emergency Medicine: Official Journal of the European Society for Emergency Medicine* 2018;25(3):221-22. doi: <https://dx.doi.org/10.1097/MEJ.0000000000000477>
38. Gassmann N, Viviano M, Fontana P, et al. Comparison of recommended postpartum thromboprophylaxis and of absolute risk thresholds according to the RCOG, ACCP and ACOG guidelines. *Research and Practice in Thrombosis and Haemostasis* 2020;4(SUPPL 1):32-33. doi: <http://dx.doi.org/10.1002/rth2.12401>
39. Gerhardt A, Scharf RE, Greer IA, et al. Hereditary risk factors for thrombophilia and probability of venous thromboembolism during pregnancy and the puerperium. *Blood* 2016;128(19):2343-49. doi: <http://dx.doi.org/10.1182/blood-2016-03-703728>
40. Gherghe M, Moss H, Gibson J, et al. Risk assessment to reduce thromboembolic disease in obstetric practice: A regional audit. *Archives of Disease in Childhood: Fetal and Neonatal Edition* 2012;97(SUPPL. 1):A49. doi: <http://dx.doi.org/10.1136/fetalneonatal-2012-301809.156>
41. Goffman D, Fisher N, Kowenski J, et al. Utilization of a checklist to evaluate risk for postpartum venous thromboembolism. *American Journal of Obstetrics and Gynecology* 2009;201(6 SUPPL. 1):S297. doi: <http://dx.doi.org/10.1016/j.ajog.2009.10.848>
42. Gomez D, Orfanelli T, Awomolo A, et al. A comparison of pregnancy-specific risk scoring systems for venous thromboembolic pharmacoprophylaxis in hospitalized maternity patients. *The Journal of Maternal-Fetal & Neonatal Medicine: The Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians* 2020:1-8. doi: <https://dx.doi.org/10.1080/14767058.2020.1832072>

43. Grille S, Castro V, Turcatti P, et al. Prophylaxis for venous thromboembolic disease in pregnancy and postpartum period. *Haematologica* 2015;100(SUPPL. 1):626.
44. Goodfellow A, Heath S, George L, et al. Perinatal venous thromboembolism state based prevention strategy: Midwifery risk assessment tool. *Thrombosis Research* 2017;151(Supplement 1):S132.
45. Grant GH, Merriman JB, Hoffman MK. Implementation and efficacy of a formalized venous thromboembolism prevention strategy in the peripartum population. *American Journal of Obstetrics and Gynecology* 2016;214(1 SUPPL. 1):S227-S28.
46. Handa S, Singh S, Bhandal N. Retrospective audit of venous thromboembolism risk assessment in obstetric postoperative patients. *Anaesthesia* 2015;70(SUPPL. 3):72. doi: <http://dx.doi.org/10.1111/anae.13136>
47. Harris C, Sulmers C, Groesch K, et al. Venous thromboembolism: Padua prediction score in the obstetric patient. *Obstetrics and Gynecology* 2016;127(Supplement 1):88S. doi: <http://dx.doi.org/10.1097/01.AOG.0000483795.00678.28>
48. Hayes-Ryan D, Byrne B. Thromboprophylaxis in pregnancy the practical implications of guidelines. *American Journal of Obstetrics and Gynecology* 2011;204(1 SUPPL.):S315-S16. doi: <http://dx.doi.org/10.1016/j.ajog.2010.10.829>
49. Hayes-Ryan D, Byrne BM. Prevention of thrombosis in pregnancy: how practical are consensus derived clinical practice guidelines? *Journal of Obstetrics and Gynaecology: The Journal of the Institute of Obstetrics and Gynaecology* 2012;32(8):740-2. doi: <https://dx.doi.org/10.3109/01443615.2012.693982>
50. Heath S, Goodfellow A. Maternal venous thromboembolism (VTE) risk assessment. *Journal of Paediatrics and Child Health* 2016;52(Supplement 2):69. doi: <http://dx.doi.org/10.1111/jpc.13194>
51. Henke PK, Pannucci CJ. Venous thromboembolism risk factor assessment and prophylaxis. *Phlebology* 2010;25(5):219-23. doi: <http://dx.doi.org/10.1258/phleb.2010.010018>
52. Kazi S, McLeod A, Berndt A. Approach to venous thromboembolism risk in women with physical disability in pregnancy-multidisciplinary survey. *Research and Practice in Thrombosis and Haemostasis* 2020;4(SUPPL 1):1283-84. doi: <http://dx.doi.org/10.1002/rth2.12393>
53. LaCoss E, Jheeta S. How accurate is information documented on inpatient electronic venous thromboembolism risk-assessment forms? *Journal of Pharmacy and Pharmacology* 2017;69(Supplement 1):13-14. doi: <http://dx.doi.org/10.1111/jphp.12850>
54. Li C, Zuo Y, Karp D, et al. Identifying clinical and epidemiological risk factors associated with thrombosis and pregnancy morbidity in a large cohort of Chinese APS patients. *International Journal of Rheumatic Diseases* 2018;21(Supplement 1):126-27. doi: <http://dx.doi.org/10.1111/1756-185X.13361>

55. Lindqvist PG. Re: Postpartum venous thromboembolism prophylaxis may cause more harm than benefit: a critical analysis of international guidelines through an evidence-based lens: Postpartum thromboprophylaxis is cost-effective using the Swedish thromboprophylaxis algorithm. *BJOG: An International Journal of Obstetrics and Gynaecology* 2018;125(9):1194-95. doi: <http://dx.doi.org/10.1111/1471-0528.15266>
56. Lindqvist PG, Hellgren M. Obstetric thromboprophylaxis: the Swedish guidelines. *Advances in hematology* 2011;2011:157483. doi: <https://dx.doi.org/10.1155/2011/157483>
57. Lindqvist PG, Kublikas M, Dahlback B. Individual risk assessment of thrombosis in pregnancy. *Acta Obstetrica et Gynecologica Scandinavica* 2002;81(5):412-6.
58. Lou Mercade AC, Saviron Cornudella R, Cornudella Lacasa R. AnticoagObs: An application for antenatal and postpartum risk assessment and prophylaxis of venous thromboembolism. *Thrombosis Research* 2017;151(Supplement 1):S127.
59. Marks D, Maiti S. Venous thromboembolism risk assessment and prescribing on the postnatal ward at north manchester general hospital: A clinical audit. *BJOG: An International Journal of Obstetrics and Gynaecology* 2018;125(Supplement 3):25. doi: <http://dx.doi.org/10.1111/1471-0528.15493>
60. McArthur L, Whittaker B, Rajasri A, et al. Venous thrombo-embolic risk in pregnancy and the puerperium: Can self-assessment identify risk and guide further care? *British Journal of Haematology* 2011;153(SUPPL. 1):84-85. doi: <http://dx.doi.org/10.1111/j.13652141.2011.08609>
61. Mpouzouki A, Bowles L, Beski S, et al. A retrospective review of risk factors for thrombosis in women presenting with venous thromboembolism (VTE) during pregnancy and the puerperium. *Thrombosis Research* 2013;131(SUPPL. 1):S82. doi: <http://dx.doi.org/10.1016/S0049-3848%2813%2970070-7>
62. Naidoo P, Mothilal R, Snyman LC. Assessment and management of venous thrombo-embolism risk during pregnancy and the puerperium (SAVE): The South African cohort. *South African Medical Journal* 2019;109(3):186-92. doi: <https://dx.doi.org/10.7196/SAMJ.2019.v109i3.13487>
63. NCT. Pregnancy and Risk of Venous Thromboembolism. <https://clinicaltrials.gov/show/NCT03659708> 2018
64. Noone CM, O'Shea S, Crowley MP, et al. Venous thromboembolism (VTE) risk assessment & prophylaxis in Irish hospitalized obstetric patients: A nationwide cross-sectional study. *Blood* 2013;122(21)
65. O'Connor C, Moriarty J, Walsh J, et al. The application of a clinical risk stratification score may reduce unnecessary investigations for pulmonary embolism in pregnancy. *The Journal of Maternal-Fetal & Neonatal Medicine: The Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International*

- Society of Perinatal Obstetricians* 2011;24(12):1461-4. doi: <https://dx.doi.org/10.3109/14767058.2011.614652>
66. O'Keefe D, Hui L, Ho P, et al. Evaluation of global coagulation assays for assessment of clotting function and risk of venous thromboembolism in pregnancy and post-partum. *Australian and New Zealand Journal of Obstetrics and Gynaecology* 2019;59(Supplement 1):68-69. doi: <http://dx.doi.org/10.1111/ajo.13067>
67. Omunakwe HE, Roberts LN, Patel JP, et al. Re: A comparison of the recommendations for pharmacologic thromboembolism prophylaxis after caesarean delivery from the major guidelines: Impact on thromboprophylaxis rates of implementing Royal College of Obstetricians and Gynaecologists' guidance for reducing the risk of ante- and postnatal venous thromboembolism. *BJOG: An International Journal of Obstetrics and Gynaecology* 2017;124(5):831-32. doi: <http://dx.doi.org/10.1111/1471-0528.14001>
68. Orfanelli T, Awomolo A, Gomez D, et al. A comparison of peripartum scoring systems of anticoagulation for venous thromboembolic prophylaxis. *Obstetrics and Gynecology* 2017;129(Supplement 1):112S.
69. O'Shaughnessy F, Donnelly JC, Cooley SM, et al. Thrombocalc: implementation and uptake of personalized postpartum venous thromboembolism risk assessment in a high-throughput obstetric environment. *Acta obstetrica et gynecologica Scandinavica* 2017;96(11):1382-90. doi: <https://dx.doi.org/10.1111/aogs.13206>
70. O'Shaughnessy F, Donnelly J, Cooley S, et al. Initiating postpartum pharmacological thromboprophylaxis: A comparison of international recommendations. *American Journal of Obstetrics and Gynecology* 2018;218(1 Supplement 1):S493-S94.
71. O'Shaughnessy F, Ni Ainle F, Jennifer D, et al. Preventing postpartum venous thromboembolism; impact of systematic VTE risk assessment. *Research and Practice in Thrombosis and Haemostasis* 2019;3(Supplement 1):225-26. doi: <http://dx.doi.org/10.1002/rth2.12227>
72. O'Sullivan C, Christensen K, Gallagher G, et al. Peripartum vte risk assessment in a tertiary centre: An audit. *Journal of Paediatrics and Child Health* 2020;56(SUPPL 1):143. doi: <http://dx.doi.org/10.1111/jpc.14868>
73. O'Sullivan C, Moriarty J, Walsh J, et al. Application of a clinical risk stratification score in pregnancy and the puerperium - Can unnecessary investigations for pulmonary embolism be avoided? *American Journal of Obstetrics and Gynecology* 2009;201(6 SUPPL. 1):S68. doi: <http://dx.doi.org/10.1016/j.ajog.2009.10.161>
74. Ottawa Hospital Research Institute, LEO Pharma. The STOP CLOT Pilot Study: Study of Low Molecular Weight Heparin in High Risk Cesarean Section: <https://ClinicalTrials.gov/show/NCT00225108>, 2002.
75. Palmerola KL, D'Alton ME, Brock CO, et al. A comparison of recommendations for pharmacologic thromboembolism prophylaxis after caesarean delivery from three major

- guidelines. *BJOG: An International Journal of Obstetrics and Gynaecology* 2016;123(13):2157-62. doi: <https://dx.doi.org/10.1111/1471-0528.13706>
76. Pannucci C, Fleming K. The electronic medical record underestimates venous thromboembolism risk using the 2005 caprini score compared with face-to-face interaction. *Journal of Vascular Surgery: Venous and Lymphatic Disorders* 2017;5(1):152-53. doi: <http://dx.doi.org/10.1016/j.jvsv.2016.10.028>
77. Pierce-Williams R, Cohen I, D'Adamo C, et al. Venous thromboembolism prophylaxis after cesarean section: A quality improvement project. *Obstetrics and Gynecology* 2018;131(Supplement 1):104S-05S.
78. Potdar N, Jabbar B, Burrell SJ. Thromboprophylaxis after vaginal delivery: a district general hospital experience. *Journal of Obstetrics and Gynaecology: The Journal of the Institute of Obstetrics and Gynaecology* 2006;26(1):24-6.
79. Rahim MN, Williamson C, Kametas NA, et al. Using pregnancy to assess risk and predict women's health. *EClinicalMedicine* 2020;20:100292. doi: <http://dx.doi.org/10.1016/j.eclinm.2020.100292>
80. Righini M, Jobic C, Boehlen F, et al. Predicting deep venous thrombosis in pregnancy: external validation of the LEFT clinical prediction rule. *Haematologica* 2013;98(4):545-8. doi: <https://dx.doi.org/10.3324/haematol.2012.072009>
81. Righini M, Le Gal G. Predicting deep venous thrombosis in pregnancy: External validation of the 'left' clinical prediction rule. *Journal of Thrombosis and Haemostasis* 2013;11(SUPPL. 3):91. doi: <http://dx.doi.org/10.1111/jth.12443>
82. Ryan N. Maternal thromboprophylaxis assessment tool: An audit. *Irish Journal of Medical Science* 2019;188(Supplement 7):S53. doi: <http://dx.doi.org/10.1007/s11845-019-02053-0>
83. Saad A, Tran JP, Stribling S, et al. Performance of risk assessment models for thromboprophylaxis in an obstetric population. *American Journal of Obstetrics and Gynecology* 2018;218(1 Supplement 1):S48-S49.
84. Santos R, Barros VV, Igai AK, et al. Maternal death and Venous Thromboembolism (VTE) in patients admitted in a maternity of high risk: Results pre and post application of a risk score. *Journal of Thrombosis and Haemostasis* 2015;13(SUPPL. 2):679. doi: <http://dx.doi.org/10.1111/jth.12993>
85. Schoenbeck D, Nicolle A, Newbegin K, et al. The use of a scoring system to guide thromboprophylaxis in a high-risk pregnant population. *Thrombosis* 2011;2011:652796. doi: <https://dx.doi.org/10.1155/2011/652796>
86. Sellappan KV, Farr R, Hill P. An audit on risk assessment of women at antenatal booking appointment. *International Journal of Gynecology and Obstetrics* 2012;119(SUPPL. 3):S703-S04. doi: <http://dx.doi.org/10.1016/S0020-7292%2812%2961724-X>

87. Shacaluga A, Wallace P, Rayment R. Abandoning RCOG Guideline 37a: A risk worth taking? *BJOG: An International Journal of Obstetrics and Gynaecology* 2017;124(Supplement 1):142. doi: http://dx.doi.org/10.1111/1471-0528.9_14572
88. Tan EK, Wisdom SJ. Thromboprophylaxis post vaginal delivery: are we forgetting it? Audit on thromboprophylaxis prescription post vaginal births. *Journal of Obstetrics and Gynaecology: The Journal of the Institute of Obstetrics and Gynaecology* 2006;26(1):27-9.
89. Tang Z, Marsden PJ. Risk assessment and management of venous thrombo-embolism in obstetric women. *Archives of Disease in Childhood: Fetal and Neonatal Edition* 2011;96(SUPPL. 1) doi: <http://dx.doi.org/10.1136/adc.2011.300163.65>
90. Taylor GM, McKenzie CA, Mires GJ. Use of a computerised maternity information system to improve clinical effectiveness: thromboprophylaxis at caesarean section. *Postgraduate Medical Journal* 2000;76(896):354-6.
91. Testa S, Paoletti O, Ronca E, et al. Health care program for thromboembolism prevention in pregnancy. *Pathophysiology of Haemostasis and Thrombosis* 2010;37(SUPPL. 1):A76. doi: <http://dx.doi.org/10.1159/000318097>
92. Testa S, Passamonti SM, Paoletti O, et al. The pregnancy health-care program: A model for the prevention of venous thromboembolism in pregnancy. *Journal of Thrombosis and Haemostasis* 2013;11(SUPPL. 2):606.
93. Touhami O, Marzouk SB, Bennasr L, et al. Are the Wells Score and the Revised Geneva Score valuable for the diagnosis of pulmonary embolism in pregnancy? *European Journal of Obstetrics, Gynecology, and Reproductive Biology* 2018;221:166-71. doi: <https://dx.doi.org/10.1016/j.ejogrb.2017.12.049>
94. Usoro E, Sakurai H, Aedla N. Investigation and management of venous thromboembolism in pregnancy. *European Journal of Obstetrics Gynecology and Reproductive Biology* 2019;234:e105. doi: <http://dx.doi.org/10.1016/j.ejogrb.2018.08.390>
95. Valdre L, Lambertini I, Palareti G, et al. Comparison of strategies for preventing venous thromboembolism in high risk pregnant women according to national and international guidelines: Results of a prospective cohort study. *Blood Transfusion* 2016;14(Supplement 5):s747.
96. Von Hawrylak F. Implementing a venous thromboembolism risk assessment in an abortion service. *European Journal of Contraception and Reproductive Health Care* 2018;23(Supplement 1):43. doi: <http://dx.doi.org/10.1080/13625187.2018.1442911>
97. Zhang W, Shen J, Sun J-L. Risk scores, prevention, and treatment of maternal venous thromboembolism. *World Journal of Clinical Cases* 2020;8(11):2210-18. doi: <https://dx.doi.org/10.12998/wjcc.v8.i11.2210>

APPENDIX S3 SIMPLIFIED SUMMARY OF WIDELY EVALUATED GENERIC RAMS, THEIR ASSOCIATED CHARACTERISTICS AND COMPOSITE CLINICAL VARIABLES

Characteristics	Name of VTE risk assessment model			
	RCOG	ACOG	SFOG	Lyon score
General				
Author, year	Royal College of Obstetricians and Gynaecologists, 2015 ¹	James et al., 2018 ²	Lindquist et al., 2008 ³ and Lindqvist & Hellgren, 2011 ⁴	Dargaud et al., 2017 ⁵
Applicable cohort	All pregnant and postpartum women	All pregnant and postpartum women at risk	Pregnant women with moderate-high risk of VTE	Pregnant women with high risk of thrombosis
Design	Risk factor based with cumulative score	Risk factor based	Risk factor based with cumulative score	Risk factor based with cumulative score
Number of VTE risk variables	26	Not specified	23	15
When is pharmacological thromboprophylaxis recommended?	<ul style="list-style-type: none"> • Score ≥ 4 antenatally (from first trimester) • Score 3 antenatally (from 28 weeks) • Score ≥ 2 postnatally (at least 10 days). • Antenatal hospital admission • Prolonged hospital admission (≥ 3 days) or readmission to hospital within puerperium 	<ul style="list-style-type: none"> • All women with acute VTE during pregnancy, or women with history of thrombosis or those at significant risk of VTE during pregnancy or the postpartum period such as those with thrombophilia 	<ul style="list-style-type: none"> • Very high risk (high dose antepartum and at least 12 weeks postpartum)^a • Score ≥ 4 (antepartum and 6 weeks postpartum) • Score 3 (after delivery [6 weeks]) • Score 2 (after delivery [7 days] or during immobilisation) 	<ul style="list-style-type: none"> • Score ≥ 6 antenatally or postnatally • Score between 3 and 5, from third trimester
Pre-existing risk factors				

Previous VTE (personal)	Yes (except a single event related to major surgery)	Yes	Yes	Yes (pregnancy related, CVT or massive PE or VTE in childhood [<16 years]; unprovoked or oestrogen related; transient risk factor induced)
Recurrent VTE	No	Yes	Yes	Yes (personal history; residual venous thrombi with clinical signs of PTS, recent <2 years)
Previous VTE provoked by specific event	Yes (major surgery)	Yes (surgery, trauma or immobility AND additional major thrombotic risk factors) ^b	No	No
Family history of VTE	Yes (unprovoked or estrogen related)	Yes (first degree with thrombophilia)	Yes (first degree <60 years)	Yes (severe or recurrent)
Thrombophilia e.g. Factor V Leiden and Factor II mutations; protein C, protein S and antithrombin deficiency; antiphospholipid syndrome (with or without VTE)	Yes (various forms)	Yes (various forms)	Yes (various forms)	Yes (various forms)
Medical comorbidities	Yes (3 points for any individual comorbidities)	No	Yes (inflammatory bowel disease)	No
Age	Yes (>35 years)	No	Yes (>40 years)	Yes (>35 years)
Obesity	Yes ($\geq 30\text{kg/m}^2$; $\geq 40\text{kg/m}^2$)	No	Yes ($>28\text{kg/m}^2$ in early pregnancy)	Yes ($\geq 30\text{kg/m}^2$)

Parity	Yes (≥ 3)	No	No	No
Smoker	Yes	No	No	No
Varicose veins	Yes (gross)	No	No	No
Hyperhomocysteinemia	No	No	Yes (homocysteine $> 8 \mu\text{mol/L}$ in pregnancy)	No
Mechanical heart prosthesis	No	No	Yes	No
Chronic warfarin prophylaxis	No	No	Yes	No
Obstetric				
Pre-eclampsia	Yes (current pregnancy)	No	Yes	No
ART/IVF	Yes (antenatal only)	No	No	No
Multiple pregnancy	Yes	No	No	Yes
Caesarean section	Yes (elective/in labour)	No	Yes	No
Mid-cavity or rotational operative delivery	Yes	No	No	No
Prolonged labour (> 24 hours)	Yes	No	No	No
Postpartum haemorrhage	Yes (> 1 litre or transfusion)	No	No	No
Preterm birth	Yes (< 37 weeks, current pregnancy)	No	No	No
Stillbirth	Yes (current pregnancy)	No	No	No
Abruptio placenta	No	No	Yes	No
Transient factors				
Any surgical procedure	Yes (pregnancy or puerperium except immediate repair of the perineum)	No	No	No
Hyperemesis	Yes	No	No	No

Ovarian hyperstimulation syndrome	Yes (first trimester only)	No	No	No
Systemic infection	Yes (current)	No	No	No
Immobility	Yes (current and dehydration)	No	Yes	Yes
Other				
‘Other risk factors’	No	No	Yes (according to clinical decision)	No

^a Thromboprophylaxis initiated as early as possible (sometimes before pregnancy). Only women with antithrombin deficiency, chronic warfarin prophylaxis, recurrent VTE, antiphospholipid syndrome with VTE, and those with mechanical heart prosthesis are included in this group

^b First-degree relative with a history of a thrombotic episode, or other major thrombotic risk factors (e.g., obesity, prolonged immobility, caesarean delivery

ACOG, American College of Obstetricians and Gynaecologists; ART/IVF Assisted reproductive technology/ In vitro fertilization; RCOG, Royal College of Obstetricians and Gynaecologists; SFOG, Swedish Society of Obstetrics and Gynecology; VTE, venous thromboembolism

REFERENCES (APPENDIX S3)

1. Royal College of Obstetricians & Gynaecologists. Thrombosis and Embolism during Pregnancy and the Puerperium, Reducing the Risk (Green-top Guideline No. 37a) 2015 [Available from: <https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg37a/> accessed January 2022.
2. James A, Birsner M, Kaimal A, et al. ACOG Practice Bulletin No. 196. Summary: thromboembolism in pregnancy. *Obstet Gynecol* 2018;132:243-8.
3. Lindqvist PG, Torsson J, Almqvist A, et al. Postpartum thromboembolism: severe events might be preventable using a new risk score model. *Vascular Health and Risk Management* 2008;4(5):1081-7.
4. Lindqvist PG, Hellgren M. Obstetric thromboprophylaxis: the Swedish guidelines. *Advances in Hematology* 2011;2011:157483. doi: <https://dx.doi.org/10.1155/2011/157483>
5. Dargaud Y, Rugeri L, Fleury C, et al. Personalized thromboprophylaxis using a risk score for the management of pregnancies with high risk of thrombosis: a prospective clinical study. *Journal of Thrombosis and Haemostasis* 2017;15(5):897-906.

